A Phase 1b Open-Label Study of the Safety and Pharmacokinetics of MEHD7945A in Combination With Either Cisplatin and 5-FU or Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Trial Profile

A Phase 1b Open-Label Study of the Safety and Pharmacokinetics of MEHD7945A in Combination With Either Cisplatin and 5-FU or Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Duligotuzumab (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Paclitaxel
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 04 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 06 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Apr 2018.
    • 06 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top